FDA Approves TASCENSO ODT — Cycle Pharmaceuticals Ltd

Cycle Pharmaceuticals Ltd announced the FDA approval of TASCENSO ODT (fingolimod lauryl sulfate), its new once-daily oral formulation for demyelinating diseases, a move that increases accessibility for patients by eliminating the need for refrigeration and simplifies administration. This approval positions the company to aggressively compete in the multiple sclerosis market by bridging the gap between intravenous and existing once-daily oral therapies.